Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

PolyPid Ltd. Ordinary Shares (PYPD)

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, and Bacyssio are trademarks of the company. The company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/26/2020

Market Cap

5,944,548

Shares Outstanding

1,640,000

Weighted SO

1,653,559

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

CUE --.--%

ANIX --.--%

INMB --.--%

INAB --.--%

EFTR --.--%

LABP --.--%

APGN --.--%

NAVB --.--%

ANGN --.--%

Beta

1.3160

Last Div

0.0000

Range

2.95-10.89

Chg

-0.0150

Avg Vol

6040

Mkt Cap

5944548

Exch

NASDAQ

Country

IL

Phone

972 7 4719 5700

DCF Diff

8.7932

DCF

-4.3934

Div Yield

0.0000

P/S

0.0000

EV Multiple

-0.5801

P/FV

11.2832

Div Yield %

0.0000

P/E

-0.7313

PEG

-0.0101

Payout

0.0000

Current Ratio

0.9506

Quick Ratio

0.9506

Cash Ratio

0.3149

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0017

ROA

-1.2650

ROE

-9.6985

ROCE

-2.5626

NI/EBT

1.0017

EBT/EBIT

1.0413

EBIT/Rev

0.0000

Debt Ratio

0.4833

D/E

5.8944

LT Debt/Cap

0.6614

Total Debt/Cap

0.8550

Int Coverage

-24.2137

CF/Debt

0.0000

Equity Multi

12.1968

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

0.0000

FCF/Share

0.0000

Cash/Share

1.8926

OCF/Sales

0.0000

FCF/OCF

0.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

11.2832

P/B

11.2832

P/S

0.0000

P/E

-0.7313

P/FCF

0.0000

P/OCF

0.0000

P/CF

0.0000

PEG

-0.0101

P/S

0.0000

EV Multiple

-0.5801

P/FV

11.2832

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 16, 23:20 PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results GlobeNewswire Inc. Dec 24, 00:22 PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX??? to 800 Patients with a Concurrent Private Placement of up to $41 Million GlobeNewswire Inc. Aug 02, 00:31 PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds GlobeNewswire Inc. Jan 04, 16:32 PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Revenue Product Segmentation